About Careers Internship MedBlog Contact us

New Formulation of FDA-Approved Drug may Help Treat Niemann-Pick Type C Disease

by Dr. Trupti Shirole on March 1, 2016 at 7:07 PM
Font : A-A+

New Formulation of FDA-Approved Drug may Help Treat Niemann-Pick Type C Disease

Niemann-Pick Type C (NPC) disease is a rare, fatal neurodegenerative disease for which there is currently no cure. New research from the University of Notre Dame may lead to a therapy for NPC.

NPC primarily strikes children before and during adolescence and affects one in every 150,000 children. The disease causes cholesterol and other lipids to build up in the body's cells, which results in symptoms such as delayed motor development, deterioration of memory and balance, and seizures.


The researchers used an existing FDA-approved drug in a novel approach to treatment with promising results. The finding involves substances known as histone deacetylase inhibitors (HDACi). HDACi are a large class of compounds designed to treat many genetic diseases. They include drugs for cancers and potentially neurological disorders.

"Unfortunately, HDACi do not cross from the blood to the brain efficiently and, in higher doses, quickly become toxic because the histone deacetylases that they block are needed for brain development and function," said Kasturi Haldar, the Nieuwland Professor in the Department of Biological Sciences and the Parsons-Quinn Director of the Boler-Parseghian Center for Rare and Neglected Diseases in the College of Science.

Haldar, Dr. Suhail Alam and Michelle Getz developed and tested a new triple combination formulation that was used to deliver the FDA-approved HDACi prescription medication Vorinostat across the blood brain barrier and into brain tissue of mice with Niemann-Pick Type C disease. They also developed a long-term treatment regimen with the formulation that is safe, improves brain function, treats the symptoms of NPC and prolongs mouse survival.

"These findings suggest that this new Notre Dame triple combination formulation may be developed as a therapy for Niemann-Pick Type C disease and possibly other types of neurological diseases as well," Haldar said.

The research findings have led to the establishment of a new company, NPC Therapeutics, by Notre Dame alumni William Claypool, class of '72, and Dennis Wilson, class of '73.

"These are very exciting results," William K. Warren Foundation Dean of the College of Science Mary Galvin said. "It is now important that the researchers determine whether the ND triple combination formulation is safe and effective in humans."

Haldar said, "We are very hopeful because all components of the formulation are separately approved for human use. The best dosing for both adults and children will have to be developed. We will also test how broadly the formulation can be used with other neurological disorders. HDACi have potential to treat many other rare neurological diseases, and our study suggests that the formulation may possibly also act with other rare diseases like Gaucher's Krabbe and Morquio, which are also rare lysosomal disorders like Niemann-Pick Type C, and rare neurological diseases like nonketotic hyperglycinemia as well as more prevalent disorders like Alzheimer's and Parkinson's. Studies on other disorders will first be done on mouse models of the disease to establish that the formulation is safe and active in treating these diseases."

Crislyn D'Souza-Schorey, Pollard Professor and chair of Notre Dame's Department of Biological Sciences, said, "This new study provides a robust foundation from which to effectively guide development of therapies for NPC and possibly other rare disorders. It is also testament to our efforts to overcome the barriers and constraints associated with studying rare diseases and influencing change at the most fundamental level."

Source: Eurekalert

News A-Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Otitis Media Signature Drug Toxicity Top Foods to Beat Chronic Fatigue Syndrome 

Most Popular on Medindia

The Essence of Yoga Blood Donation - Recipients Drug Interaction Checker Turmeric Powder - Health Benefits, Uses & Side Effects Calculate Ideal Weight for Infants Accident and Trauma Care Iron Intake Calculator Hearing Loss Calculator How to Reduce School Bag Weight - Simple Tips Pregnancy Confirmation Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use

New Formulation of FDA-Approved Drug may Help Treat Niemann-Pick Type C Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests